Polygenic risk scores (PRS) have been gaining attention as a key innovation in genomic medicine, offering probabilistic risk estimates of common complex diseases from inherited susceptibility. By aggregating the small effects of numerous common genetic variants, PRS may improve risk stratification at both individual and population levels, supporting preventive and broader health care strategies. In recent years, discussions on prospective clinical uses of PRS have increased considerably, with ongoing debate about how PRS should be interpreted and communicated.